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ABSTRACT 
Background: Data on patient-reported outcomes (PROs) in adults with congenital heart 
disease (CHD) are inconsistent and vary across the world. Better understanding of PROs and 
their differences across cultural and geographic barriers can best be accomplished via 
international studies using uniform research methods. The APPROACH-IS consortium 
(Assessment of Patterns of Patient-Reported Outcomes in Adults with Congenital Heart 
disease – International Study) was created for this purpose and investigates PROs in adults 
with CHD worldwide. This paper outlines the project rationale, design, and methods.  
Methods/Design: APPROACH-IS is a cross-sectional study. The goal is to recruit 3,500-
4,000 adults with CHD from 15 countries in five major regions of the world (Asia, Australia, 
Europe, North and South America). Self-report questionnaires are administered to capture 
information on PRO domains: (i) perceived health status (12‐item Short‐form Health Survey 
& EuroQOL-5D); (ii) psychological functioning (Hospital Anxiety and Depression Scale); 
(iii) health behaviors (Health-Behavior Scale–Congenital Heart Disease); and (iv) quality of 
life (Linear Analog Scale & Satisfaction With Life Scale). Additionally, potential explanatory 
variables are assessed: (i) socio-demographic variables; (ii) medical history (chart review); 
(iii) sense of coherence (Orientation to Life Questionnaire); and (iv) illness perceptions (Brief 
Illness Perception Questionnaire). Descriptive analyses and multilevel models will examine 
differences in PROs and investigate potential explanatory variables. 
Discussion: APPROACH-IS represents a global effort to increase research understanding and 
capacity in the field of CHD, and will have major implications for patient care. Results will 
generate valuable information for developing interventions to optimize patients’ health and 
well-being.  
Registration: ClinicalTrials.gov: NCT02150603. 
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1. Background 
Worldwide, congenital heart disease (CHD) is the most common birth defect with a 
global prevalence of 9.3 per 1,000 newborns [1]. Over the past few decades, the number of 
adults with CHD has risen considerably as almost 90% of children with CHD now survive 
into adulthood [2, 3]. Adults with CHD now form more than 60% of the total CHD population 
[4]. These adults are confronted with life-long cardiac and non-cardiac challenges and 
comorbidities [5]. Hence, a strong need has been identified by the CHD community to attend 
to aspects important to the patient beyond the medical arena, such as psychosocial functioning 
and quality of life (QOL) [6]. As a result, there has been much interest in research assessing 
patient-reported outcomes (PROs) in adults with CHD. PROs are defined by the US Food and 
Drug administration as “any reports of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response by a clinician or 
anyone else” [7]. In addition to understanding the entire patient experience, PROs are of 
clinical significance in cardiovascular patient populations [8]. For example, poor perceived 
health status predicts hospitalization and mortality in patients with chronic heart failure and 
coronary artery disease [9]. Consequently, investigation of PROs within cardiovascular 
research is increasingly advocated [10]. 
Studies on perceived health status, health behaviors, psychological outcomes, and QOL 
in the field of CHD have reported inconsistent results. While some studies have shown that 
adults with CHD perceived their health status similar to controls [11, 12], others have found 
that perceived health status was lower in patients with CHD than in controls [13]. Several 
studies reported that patients with CHD displayed more emotional problems than their healthy 
counterparts [14-19]. For example, Kovacs et al. reported that 50% of patients met the 
 
 
diagnostic criteria for at least one mood or anxiety disorder at some point in their lives [20]. 
However, a recent meta-analysis concluded that results on emotional problems are equivocal 
in the CHD research literature [21]. Prior research has highlighted the high prevalence of 
unhealthy behaviors in individuals with CHD. For instance, over half of young adults with 
CHD reported substance use in a Canadian study [22]. Numerous studies have demonstrated 
compromised QOL in patients with CHD [23]. However, existing data are not consistent, and 
several studies have indicated that outcomes in patients with CHD were comparable to 
healthy individuals [23-29], or even better than healthy peers [23]. For instance, studies 
conducted in the Netherlands [30] and Belgium [11] generally reported superior outcomes to 
those performed in the US [13]. As such, researchers are unsure to what extent their findings 
are generalizable worldwide. Furthermore, the role of potential explanatory variables (e.g., 
sense of coherence or illness perception) contributing to such international variation is not 
well understood.  
This inconsistent pattern of findings raises important unanswered questions as to (i) 
whether differences in previously reported PROs are the result of methodological issues or 
regional differences; and if genuine differences do exist, (ii) whether influencing factors can 
be identified. Indeed, although PROs have been reported in many countries, scores may vary 
due to the influence of culture-bound or national factors on patients’ subjective well-being 
[31]. However, variations between populations and regions may also be attributable to 
differences in study design and methodological shortcomings, such as small sample sizes and 
the use of questionnaires with weak psychometric properties [23]. No previous international 
study has focused on PROs in adults with CHD. Further, few studies in patients with CHD 
have included a comprehensive set of PROs. 
Key questions about patient-reported health and well-being on a global stage can best be 
answered by a large international study in which a broad set of PROs is measured in a 
 
 
uniform manner, and potentially influencing factors are obtained in all countries. Indeed, 
global challenges require global collaboration. This prompted the establishment of the 
APPROACH-IS consortium. APPROACH-IS is the acronym for Assessment of Patterns of 
Patient-Reported Outcomes in Adults with Congenital Heart disease – International Study. 
The purpose of this paper is to describe the rationale, design, and methods of APPROACH-IS, 
thereby providing a thorough background for future reports emerging from this project. 
2. Study aims 
The primary aim is to assess potential differences in four categories of PROs (perceived 
health status, psychological functioning, health behaviors, and QOL) in adults with CHD who 
are living in different areas of the world. The secondary aim is to gain insight into how 
international differences can be understood. For example, the present project focuses on 
potential differences in illness perceptions or sense of coherence to explain international 
variation in QOL. 
3. Design and methods 
3.1 Project design 
APPROACH-IS is a large international, cross-sectional study conducted in 
collaboration with the International Society for Adult Congenital Heart Disease (ISACHD).  
3.2 Settings 
For this multi-country project, participating centers were selected by the APPROACH-
IS steering committee based on feasibility (e.g., personnel and financial resources), 
willingness to participate, geographical distribution, and patient volume to ensure sufficient 
variability and recruitment of an adequate number of patients representing the entire spectrum 
of cardiac lesions (i.e., simple, moderate, and complex lesions). Overall, 24 centers across 15 
 
 
countries (Argentina, Australia, Belgium, Canada, France, India, Italy, Japan, Malta, Norway, 
Taiwan, the Netherlands, Sweden, Switzerland, and USA) agreed to participate (Fig. 1).  
 
Fig. 1 Geographic distribution of the APPROACH-IS participating centers. 
3.3 Sample 
The recruitment goal of APPROACH-IS is to enroll 200 adults with CHD from each of 
the 24 participating centers, resulting in a sample size of 4,800 patients. However, in 
recognition of the fact that not all centers will be able to achieve this goal, we estimate that 
the total sample will be 3,500 to 4,000 patients. The inclusion criteria are as follows: (i) 
diagnosis of CHD, defined as a structural abnormality of the heart or intra-thoracic great 
vessels that is present at birth and is actually or potentially functionally significant (including 
mild, moderate, and severe heart defects) [32]; (ii) 18 years of age or older; (iii) diagnosis 
established before the age of 10 (i.e., before adolescence to warrant sufficient experience of 
living with CHD); (iv) continued follow-up at a CHD center or included in a national/regional 
registry; and (v) physical, cognitive, and language capabilities required to complete the self-
report questionnaires. Patients are excluded from study participation if they (i) underwent 
 
 
prior heart transplantation; (ii) have primary pulmonary hypertension; or (iii) have impaired 
cognitive abilities. 
3.4 Project management 
Coordination of APPROACH-IS is carried out by the University of Leuven (KU 
Leuven, Belgium). The coordinating center is responsible for the overall administration of the 
study, as managed by the international project coordinator (SA). Furthermore, the steering 
committee is responsible for overseeing all aspects of the international study, decision-
making, and has final responsibility for scientific conduct. The steering committee is 
comprised of three investigators participating in this study, one nurse researcher (PM) and 
two psychologists (AK, KL). Each of the participating centers is overseen by the local 
principal investigator, who is responsible for all aspects of study implementation at the local 
level. 
To streamline the processes of data collection and data management, standard operating 
procedures (SOPs) were developed for ethics approval; study preparation; study 
administration; recruitment and survey completion; data storage, entry and security; study 
progress; and publication policy. The SOPs allow for flexibility in terms of data collection 
(i.e., recruitment options) and data entry (i.e., online data entry vs. direct data entry into a 
statistical database). All data are transferred to the coordinating center where quality-control 
checks and statistical analyses are conducted. The coordinating center also created a website 
to share materials and methods (http://approach-is.net) Error! Hyperlink reference not valid.as 
well as distributing monthly information flashes to update the participating centers and other 
interested parties about study progress. 
3.5 Data collection procedures 
 
 
Participants are surveyed using a set of self-reported questionnaires. Participating 
centers can choose between two recruitment and data collection strategies. The first strategy is 
to randomly select eligible patients from their institution’s database. These patients will then 
be mailed a study package including: (i) a study information letter; (ii) a copy of the survey 
package; (iii) the informed consent form (if required); and (iv) an addressed, prestamped 
return envelope. Patients are asked to complete the questionnaires within two weeks. Various 
approaches will be used to maximize response rates (e.g., mail or telephone reminders) [33]. 
However, to compensate for a potential nonresponse rate of up to 50%, which is generally 
anticipated in postal surveys [34], a minimum of 400 eligible patients per center will be 
selected. Three weeks after the first mail-out, a reminder will be sent to those who have not 
yet returned completed questionnaires. We expect a response rate of approximately 25% (i.e., 
100 patients) after the initial mailing and hope to double the response through a reminder (i.e., 
50% response rate or 200 patients) [35, 36].  
A second recruitment strategy is to consecutively approach eligible patients at 
outpatient clinics. Patients who consent to participate will complete surveys during their clinic 
visit and return them to the research assistant or data collection officer. Patients may also be 
given the opportunity to return surveys by self-addressed stamped envelope.  
In addition, regardless of the chosen recruitment strategy, a member of the research 
team from each participating center reviews participants’ medical records in order to allow us 
to (i) describe the medical background of study participants and (ii) to investigate whether 
PROs vary as a function of medical variables. Data abstraction includes primary CHD 
diagnosis, disease complexity, surgical history, etc. Any documented history of a mood or 
anxiety disorder or other psychiatric diagnosis is also recorded. 
 
 
Participating centers are individually responsible for the data collection process. Data 
collection for this project commenced in April 2013 and will be completed by December 
2014. 
4. Patient-reported outcome measures (PROs) 
Participants complete a background information questionnaire focused on socio-
demographic variables. The format of certain items varies between countries to reflect local 
standards (e.g., disability may be reported as a percentage or be divided into four categories).  
Standardized questionnaires are used to measure primary and secondary outcomes. 
These questionnaires were chosen based on their sound psychometric properties, extensive 
use in previous studies, and availability in different languages. Table 1 presents an overview 
of the core battery of APPROACH-IS questionnaires and their psychometric properties.  
If a certain questionnaire was not available in a specific language, a standard academic 
translation protocol was followed by the local research team. The protocol was comprised of 
the following steps: (i) forward translation; (ii) backward translation; (iii) pilot testing in 
patients; (iv) proofreading and finalization; and (v) report. All participating centers were 
advised to use the methodology as described by the Mapi Research Institute as a guide. 
Centers were asked to send the results of this process to the coordinating center. No 
substantial changes to the English template of the respective questionnaires were permitted. 
  
 
 
Table 1 
Variables measured in APPROACH-IS. 
 Source Measurements Required 
translations 
Validity  Reliability  Responsiveness  Interpretation  
Socio-demographic variables        
- Age 
- Sex 
- Marital status 
- Presence of children 
- Student status 
- Educational level 
- Employment status 
- Patient-reported New York 
Heart Association 
assessment 
- Religion 
Patient 
self-
report 
Survey developed by 
research team 
Chinese, Dutch, 
French, 
German, Hindi, 
Italian, 
Japanese, 
Norwegian, 
Spanish, 
Swedish, and 
Tamil 
NA NA NA NA 
Medical history        
- Congenital heart disease 
diagnosis 
- Complexity of heart defect 
- Cardiac 
surgeries/interventions 
- History of congestive heart 
failure/arrhythmia/other 
medical condition 
- Cardiac device 
implantation 
- Cognitive impairment 
- Frequency of follow-up 
- Cardiac admission (total 
number since age 18) 
- Chart-documented mood 
Chart 
review 
Survey developed by 
research team 
Chinese, Dutch, 
French, 
German, Hindi, 
Italian, 
Japanese, 
Norwegian, 
Spanish, 
Swedish, and 
Tamil 
NA NA NA NA 
 
 
or anxiety disorder or 
another psychiatric 
diagnosis 
Primary outcomes        
Perceived health status Patient 
self-
report 
12‐item Short‐form 
Health Survey  
version 2 (SF-12) 
NA Confirmed in 
medical 
populations 
[40] 
Confirmed in 
medical 
populations 
[40] 
Confirmed in 
medical 
populations 
[40] 
Scores from 0 
to 100 on eight 
health 
domains; 
higher scores 
= better 
perceived 
health 
EuroQol-5D 3 level 
version (EQ-5D) 
NA Construct 
validity 
confirmed in 
cardiovascular 
patient 
populations 
[55] 
Confirmed in 
cardiovascul
ar patient 
populations 
[55] 
Confirmed in 
cardiovascular 
patient 
populations 
[55] 
Scores from 1 
(no problems) 
to 3 (extreme 
problems) on 
five 
dimensions; 
score from 0 
(worst 
imaginable 
health state) to 
100 (best 
imaginable 
health state) 
Psychological functioning Patient 
self-
report 
Hospital Anxiety and 
Depression Scale 
(HADS) 
NA Confirmed in 
medical 
populations 
[56, 57] 
Confirmed in 
medical 
populations 
[56, 57] 
NR Subscale 
scores range 
from 0 to 21; 
higher scores 
= more 
symptoms 
Health behaviors Patient Health-Behavior Chinese, Content validity Stability not Confirmed in Substance use 
 
 
self-
report 
Scale–Congenital 
Heart Disease (HBS-
CHD) 
French, 
German, Hindi, 
Italian, 
Japanese, 
Norwegian, 
Spanish, 
Swedish, and 
Tamil 
and validity 
based on 
relationship 
with other 
variables 
confirmed in 
adolescents 
with congenital 
heart disease 
[44] 
yet 
confirmed 
[44] 
adolescents 
with congenital 
heart disease 
[44] 
risk score (0-
100); dental 
hygiene risk 
score (0-100); 
physical 
exercise score 
(0-∞); total 
health risk 
score (0-100) 
Quality of life Patient 
self-
report 
Linear Analog Scale 
(LAS) 
Chinese, 
French, 
German, Hindi, 
Italian, 
Japanese, 
Norwegian, 
Spanish, 
Swedish, and 
Tamil 
Test content 
and validity 
based on 
relationship 
with other 
variables 
confirmed in 
adults with 
congenital heart 
disease [11] 
Test-retest 
reliability 
confirmed in 
adults with 
congenital 
heart disease 
[11] 
Confirmed in 
adults with 
congenital heart 
disease [11] 
Scores from 0 
(worst 
imaginable 
quality of life) 
to 100 (best 
imaginable 
quality of life) 
Satisfaction with Life 
Scale (SWLS) 
Tamil Test content 
and validity 
based on 
relationship 
with other 
variables 
confirmed in 
adults with 
congenital heart 
disease [11] 
Internal 
consistency 
and test-
retest 
reliability 
confirmed in 
adults with 
congenital 
heart disease 
[11] 
Confirmed in 
adults with 
congenital heart 
disease [11] 
Total score 
from 5 
(extremely 
dissatisfied) to 
35 (extremely 
satisfied) 
Secondary outcomes        
Sense of coherence Patient 13 item Orientation Tamil Structural Internal Confirmed in Total score 
 
 
self-
report 
to Life Questionnaire 
(SOC-13) 
validity 
confirmed in 
adolescents 
with congenital 
heart disease 
[58]; Face, 
consensual, 
construct, 
criterion, and 
predictive 
validity 
confirmed in 
different 
populations 
[59] 
consistency 
and test-
retest 
reliability 
confirmed in 
different 
populations 
[59] 
different 
populations 
[59] 
from 13 to 91; 
higher values 
= stronger 
sense of 
coherence 
Illness perceptions Patient 
self-
report 
Brief Illness 
Perception 
Questionnaire (Brief 
IPQ) 
Tamil Concurrent 
validity 
confirmed in 
adults with 
renal disease, 
diabetes, and 
asthma; 
predictive 
validity 
confirmed in 
adults with 
myocardial 
infarction; 
discriminant 
validity 
confirmed in 
adults with 
Test-retest 
reliability 
confirmed in 
adults with 
renal disease 
[53] 
NR Scores from 0 
to 10 on eight 
dimensions; 
higher scores =  
more 
threatening 
view of the 
illness 
 
 
diabetes, 
asthma, colds, 
myocardial 
infarction, and 
chest pain [53] 
NA: not applicable; NR: not reported. 
 
  
 
 
4.1. Primary outcomes 
Four PRO domains are measured: perceived health status, psychological functioning, 
health behaviors, and QOL (Table 1).  
First, perceived health status is defined as the impact of a disease according to the 
patient, including symptoms, functional status, and health-related QOL [37]. We use two 
disease-generic measures to assess patients’ perceived health status: the 12‐item Short‐
Form Health Survey version 2 (SF‐12v2) and the EuroQol-5D 3 level version (EQ-5D-3L). 
Studies have confirmed the psychometric properties of both scales, but for this project we 
chose to include both the SF-12 and EQ-5D to ensure coverage of a broad range of health 
dimensions [38, 39]. The SF-12 measures eight health domains: physical functioning, role 
participation with physical health problems, bodily pain, general health, vitality, social 
functioning, role participation with emotional health problems, and mental health. Scores 
range from 0 to 100 and higher scores reflect better perceived health status [40]. The SF-12 
also produces a Mental Component Summary and a Physical Component Summary. The EQ-
5D comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) which are rated at three levels (no problems, some problems, or extreme 
problems). The EQ-5D also includes a visual analog scale ranging from 0 (best imaginable 
health state) to 100 (worst imaginable health state) [41].  
Second, we focus on two categories of psychological functioning, namely symptoms of 
anxiety and depression. The Hospital Anxiety and Depression Scale (HADS) was specifically 
developed for use with medical populations and produces two seven-item subscales (i.e., 
HADS-Anxiety and HADS-Depression). Subscale scores range from 0 to 21 with higher 
scores reflecting greater psychological distress [42]. Subscale scores of eight or higher reflect 
clinically-elevated symptomatology. 
 
 
Third, health behaviors are defined as activities that a person undertakes to prevent 
disease or to improve health and well-being [43]. Two types of health behaviors can be 
distinguished: health enhancing (e.g., physical exercise) and health compromising behaviors 
(e.g., smoking). The Health-Behavior Scale–Congenital Heart Disease (HBS-CHD) was 
chosen to measure both behaviors. The HBS-CHD evaluates alcohol consumption (e.g., 
frequency), tobacco use (e.g., number of cigarettes), dental care (e.g., last dental visit), and 
physical activity (e.g., during leisure time). This information generates four risk scores: a 
substance use risk score (0-100), a dental hygiene risk score (0-100), a physical exercise score 
(0-∞), and a total health risk score (0-100). A higher risk score represents an unhealthier 
behavior [44]. 
Fourth, QOL was conceptually defined as the degree of overall life satisfaction [45]. A 
Linear Analog Scale (LAS) is the recommended method to rate overall QOL [45]. The LAS is 
a vertically oriented, 10-centimeter line graded with indicators from 0 (worst imaginable 
QOL) to 100 (best imaginable QOL) [45]. Furthermore, the Satisfaction With Life Scale 
(SWLS) is used as a second indicator of QOL and assesses a person’s global judgment of life 
satisfaction [46]. The SWLS comprises five statements with a response scale ranging from 1 
(strongly disagree) to 7 (strongly agree). A score of 20 represents the neutral point on the 
scale.  
4.2. Secondary outcomes 
Two psychosocial explanatory variables will also be measured (Table 1). The first is 
sense of coherence, representing a person’s generalized world view that characterizes the 
extent to which a person perceives: (i) stimuli as structured and predictable; (ii) that resources 
are available to meet the demands posed by these stimuli; and (iii) that these demands are 
challenges worthy of investment. Hence, people with a strong SOC perceive the world as (i) 
comprehensible, (ii) manageable, and (iii) meaningful [47]. Previous studies in patients with 
 
 
CHD have highlighted the importance of considering sense of coherence in relation to PROs 
[48, 49]. Therefore, sense of coherence is evaluated in this study using the 13-item 
Orientation to Life Questionnaire [47, 50]. A seven-point semantic differential scale ranging 
from 1 (very seldom or never) to 7 (very often) assesses the three components of sense of 
coherence: (i) comprehensibility (five items); (ii) manageability (four items); and (iii) 
meaningfulness (four items). The total score ranges from 13 to 91 with a higher score 
indicating a stronger sense of coherence.  
Second, patients’ illness perceptions will be evaluated. Illness perceptions are defined as 
the cognitive representations and beliefs that patients have about their illness [51] and have 
also been related to PROs in adults with CHD [52]. The Brief Illness Perception 
Questionnaire (Brief IPQ) is administered to assess cognitive and emotional representations 
of illness on a nine-item scale [53]. Items are rated from 0 to 10 and evaluate consequences, 
timeline, personal control, treatment control, identity (i.e., cognitive representations), concern, 
and emotions (i.e., emotional representations). The Brief IPQ also includes an item that 
assesses illness comprehensibility and another that inquires about perceived causal factors.  
5. Quality control 
Quality checks are performed by the coordinating center on data from the first 10 
participants from each participating center. As such, any systematic errors can be addressed 
prior to further data entry. After performing preliminary analyses of all center-specific 
datasets to identify out-of-range and missing values, or possible remaining data entry errors, a 
cleaned version of these datasets will be organized into one overarching multi-country 
database. 
6. Data analysis 
 
 
First, descriptive and comparative analyses of PRO variables reflecting commonalities 
and differences will be performed. Data will be summarized separately for each participating 
center as counts and percentages for categorical variables and means and standard deviations 
for normally distributed continuous variables. Descriptive statistics will be reported for all 
participating centers and countries. 
Second, relationships between PROs and potential explanatory variables will be 
examined. Special attention will be given to missing data by means of multiple imputation 
models. Sample size variations will be accounted for in the statistical methods. Given that the 
collected data is hierarchical, multilevel analysis will be employed. More specifically, data 
will be organized at three levels: (i) the individual patient level; (ii) the center level; and (iii) 
the country level. Individual patient data are nested within center and country levels 
(aggregate units). This project will allow for inter-country comparative analysis of the extent 
to which PROs differ, and in certain cases also for intra-country analysis (e.g., between 
American centers). Statistical significance will be defined as p≤0.05 with appropriate 
adjustments for multi-testing. 
Given the richness of the data, substudies will be planned in accordance with ideas 
generated by participating centers. Substudies will be performed after the primary analyses 
have been conducted and reported.  
7. Ethical issues 
The overarching study protocol was approved by the Institutional Review Board of the 
University Hospitals Leuven/KU Leuven (i.e., the coordinating center). Additionally, ethical 
approval was obtained by each participating center, if required. Although informed consent 
will be obtained from all participants in most centers, there are some countries in which 
national legislation stipulates that written consent for survey studies is not required.  
 
 
Maintaining participant confidentiality is deemed a high priority. No personal health 
information (e.g., name, medical record number, or date of birth) is sent from the participating 
centers to the coordinating center. A unique patient study identification code consists of a 
two-digit center identification code followed by a three-digit patient identification number. 
For example, code 01-001 represents the first patient recruited from the first participating 
center.  
APPROACH-IS follows the recommendations of the Declaration of Helsinki II [54]. 
The authors of this manuscript have certified that they comply with the Principles of Ethical 
Publishing in the International Journal of Cardiology. The study protocol was recorded at 
ClinicalTrials.gov: NCT02150603. 
8. Current status of the project 
We anticipate that data collection will be completed by the end of December 2014. Data 
quality checks and clarifications are performed on an ongoing basis. Data will be analyzed 
during the first six months of 2015. We foresee that the primary results of this study will be 
available in the second half of 2015.  
9. Discussion 
Adults with CHD represent a growing and aging patient population [2]. As survival 
rates continue to improve, patient well-being will continue to be a priority for healthcare 
professionals worldwide. At the present time, consistent data on PROs in adults with CHD 
from well-designed studies are lacking. The APPROACH-IS collaborative will provide a 
definitive contribution towards resolving this issue. As the largest collaborative thus far 
established across a wide cultural and regional diverse population, APPROACH-IS will 
extend the results from previous single-center or regional multi-center studies by 
incorporating collaborators from different regions in the world. The use of a strong, uniform 
 
 
methodology will ensure consistent and reliable data, and will also lead to the further 
development of research capacity among all participating adult CHD centers. Furthermore, 
the resulting international dataset will be a valuable resource for researchers and healthcare 
professionals alike in the field of CHD. In addition, data may serve as a historical cohort to 
which future samples may compare. Indeed, APPROACH-IS will generate a comparable 
dataset from adult CHD centers around the world whose pooled results can inform 
(inter)national policy. 
A few study limitations must be acknowledged. First, APPROACH-IS is a cross-
sectional study, and thus causality cannot be determined. However, some centers have opted 
to follow the participants on a longitudinal basis. Second, study results may not be 
generalizable to patients with CHD who are not being followed in CHD programs in 
participating countries, to adults with CHD in other countries, or to patients who do not 
receive ongoing CHD follow up. Third, patients who are physically or mentally not capable of 
completing the questionnaires are not represented in this study. Fourth, we acknowledge that 
it is not possible to determine the impact of all possible factors (e.g., undiagnosed syndromes 
or family history of mental health problems) on PROs. 
In summary, APPROACH-IS should result in significant scientific and clinical 
contributions by increasing our understanding of PROs in adults with CHD, with the focus on 
international differences and potential explanatory variables. As such, we hope that this 
project will prompt the development of future interventions designed to address the health and 
well-being of patients with CHD around the world.  
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